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Mutations in Calmodulin Cause Ventricular
Tachycardia and Sudden Cardiac Death
Mette Nyegaard,1,8,* Michael T. Overgaard,2,8 Mads T. Søndergaard,2 Marta Vranas,1 Elijah R. Behr,3
Lasse L. Hildebrandt,2 Jacob Lund,2 Paula L. Hedley,4,5 A. John Camm,3 Go¨ran Wettrell,6 Inger Fosdal,7
Michael Christiansen,4 and Anders D. Børglum1,*
Catecholaminergic polymorphic ventricular tachycardia (CPVT) is a devastating inherited disorder characterized by episodic syncope
and/or sudden cardiac arrest during exercise or acute emotion in individuals without structural cardiac abnormalities. Although rare,
CPVT is suspected to cause a substantial part of sudden cardiac deaths in young individuals. Mutations in RYR2, encoding the cardiac
sarcoplasmic calcium channel, have been identified as causative in approximately half of all dominantly inherited CPVTcases. Applying
a genome-wide linkage analysis in a large Swedish family with a severe dominantly inherited form of CPVT-like arrhythmias, wemapped
the disease locus to chromosome 14q31-32. Sequencing CALM1 encoding calmodulin revealed a heterozygous missense mutation
(c.161A>T [p.Asn53Ile]) segregating with the disease. A second, de novo, missense mutation (c.293A>G [p.Asn97Ser]) was subsequently
identified in an individual of Iraqi origin; this individual was diagnosed with CPVT from a screening of 61 arrhythmia samples with no
identified RYR2mutations. Both CALM1 substitutions demonstrated compromised calcium binding, and p.Asn97Ser displayed an aber-
rant interactionwith the RYR2 calmodulin-binding-domain peptide at low calcium concentrations.We conclude that calmodulin muta-
tions can cause severe cardiac arrhythmia and that the calmodulin genes are candidates for genetic screening of individual cases and
families with idiopathic ventricular tachycardia and unexplained sudden cardiac death.Idiopathic ventricular tachycardia (VT) is a cardiac
arrhythmia that is seen in individuals without structural
heart disease. Depending on the ECG characteristics, it
can be classified as monomorphic VT or polymorphic VT,
the latter comprising a number of uncommon, often
malignant familial disorders, including catecholaminergic
polymorphic VT (CPVT [MIM 604772]).1 CPVT is charac-
terized by episodic syncope and/or sudden cardiac arrest
induced by exercise or acute emotion.2,3 The ECG is
usually within normal limits at rest and often displays
prominent U waves, but ventricular arrhythmias might
arise at times of adrenergic activation.4,5 The arrhythmias,
typically bidirectional and/or polymorphic VT, can
develop into ventricular fibrillation and sudden death,
leading to a high mortality rate (30%–50% by the age of
30) for this disorder.6 CPVT often manifests in childhood,
and a family history of juvenile sudden death and stress-
induced syncope is present in approximately one-third of
the cases. It can present as sudden death in children
without any prior signs or warning,6 and it has been esti-
mated to cause up to 15% of unexplained sudden cardiac
deaths in young people.7 Previously, familial assessment
revealed little evidence of the condition in many victims
of unexplained sudden death.8,9 Mutations in the ryano-
dine receptor 2 gene (RYR2 [MIM 180902]) are known to
cause dominantly inherited CPVT10 (CPVT1 [MIM
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The Americcurrently known. A less common autosomal-recessive
form of the disorder (CPVT2 [MIM 611938]) is caused by
mutations in the calsequestrin-2 gene11 (CASQ2 [MIM
114251]). Mutations in these genes together explain a little
more than half of all familial CPVT cases. Mutations in
KCNJ2 [MIM 600681] and ANK2 [MIM 106410], normally
causing Andersen-Tawil Syndrome (ATS [MIM 170390])
and type 4 long-QT syndrome (LQT4 [MIM 600919]),
respectively, have in addition been found in a low number
of individuals diagnosed with CPVT.12,13 Finally, a locus
for a severe form of CPVT (CPVT3 [MIM 614021]) was in
2007 localized to chromosome 7without the identification
of the disease gene.14
Tightly controlled cycling of the intracellular calcium
concentration is the basis for cardiac muscle contraction
and determination of the heart rhythm. RYR2 is the sarco-
plasmic reticulum (SR) calcium release channel. Upon
a small increase in local intracellular Ca2þ concentration
(from approximately 100 nM to a few micromolar), this
channel switches from a closed to an open conformation,
resulting in a large influx of Ca2þ from the SR storage and
ultimately causing muscle contraction. The current molec-
ular understanding of RYR2-associated VT is that RYR2
mutations render the tetrameric RYR2 complex ‘‘leaky,’’
thereby leading to increased local Ca2þ concentrations
(Ca2þ sparks), untimely activation of nearby RYR2 clusters
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Figure 1. Pedigree and Electrocardiography
(A) Pedigree of Swedish family with the chromosome 14 haplotypes presented graphically with HaploPainter.18 The index case is
indicated with an arrow. The individuals included in the initial SNP genome-wide linkage analysis are marked by an asterisk.
(B) The ECG during rest and an arrhythmia event (while the individual was playing football) occurring during a 24 hr ECG registration of
the index case II:6 of family 1.
(C) Resting and exercise ECGs from a second, unrelated individual of Iraqi origin. Both resting ECGs demonstrate prominent U waves in
the anterior leads, and bidirectional ventricular ectopy is seen during physical activity or exercise.eventual arrhythmia.15,16 The precise molecular mecha-
nism is, however, still unclear, and it has been put forward
that an abnormal interaction with one or more of the asso-
ciated proteins or ions, such as FKBP12.6 or CASQ2, or
abnormal activation by extraluminal or intraluminal
Ca2þ ions also might play a role, as reviewed by Kontula
et al.16 and Mohler et al.17
Here we report a Swedish multiplex family presenting
with a history of ventricular arrhythmias, syncopes and
sudden death, predominantly in association with physical704 The American Journal of Human Genetics 91, 703–712, Octoberexercise or stress (Figure 1A). The index case (II:6), a now
42-year old man of Swedish ethnic origin, presented with
syncope while playing football at the age of 12. The ECG
at admission (Figure 1B, upper panel) showed sinus brady-
cardia (HR ¼ 45/min) and prominent U-wave in V2 and
V3, but no evidence of QT prolongation (QTc ¼ 0.42 s).
He had a history of loss of consciousness on at least four
occasions during physical activity and once in connection
with a fire alarm. A 24 hr ECG registration revealed
ventricular extrasystoles (VES), bigemini, and paired5, 2012
VES (Figure 1B, lower panel) during football training,
but no symptoms were reported. He was started on
b1-adrenergic-receptor blocker treatment. At follow up,
a 24 hr ECG and exercise test still showed some VES and
bigemini under conditions of increasing load and heart
rate. A genomic DNA sample from the index case was later
screened for mutations in a panel of arrhythmia-associated
genes, including RYR2 and CASQ2, where no mutations
were identified. An older brother (II:4), aged 23, had a
history of repeated syncope during exercise. During an
exercise test, he displayed polymorphic VT (an ECG from
that time is not available). After treatment with b1-adren-
ergic-receptor blocker, a follow-up exercise test showed
VES at high loads. The family history also included a
brother (II:3) who drowned during a swimming competi-
tion at age 15 after having had prior episodes of syncope
and an older sister (II:2) who suffered from fits or syncope.
After a later episode of ventricular fibrillation (VF), she
was stabilized by treatment with b1-adrenergic-receptor
blocker and became asymptomatic. A younger sister (II:8)
presented at the age of 7 with a history of repeated syncope
during intense physical activity. One younger family
member (III:5), with reported syncope from age 2.5,
died suddenly at age 13, having been treated with
b1-adrenergic-receptor blocker for several years. Another
family member (III:4) started having syncope at age 4,
was asymptomatic under treatment with b1-adrenergic-
receptor blocker, and suffered cardiac arrest at age 16. After
rapid defibrillation and resuscitation, she recovered and
had an ICD implanted. An older sister (III:2) presented
with syncope from age 6–7 and became asymptomatic
under treatment with b1-adrenergic-receptor blocker. A
younger sister (III:6) presented with syncope at age 3–4.
Family members III:9, III:12, and IV:1 were put on
b1-adrenergic-receptor blocker after having suffered
syncope and attacks of dizziness. According to the family,
subject I:1 suffered multiple cases of syncope in her youth
and was on medication. She died at 60 years old. Thus, the
phenotypic picture of the family is characterized by CPVT-
like features with symptoms including frequent syncope
and three cases of sudden death or cardiac arrest. The
affected family members display no other apparent clinical
manifestations.
All procedures were in accordance with the ethical
standards of the responsible committees (institutional
and national) on human experimentation. After obtaining
informed consent from all the subjects, we extracted
genomic DNA from peripheral blood samples from
all the subjects to perform linkage analysis. Initially, 12
subjects (nine affected and three unaffected, indicated by
an asterisk in Figure 1A) were genotyped with the Human
Mapping 50K SNP Xba240 Array (Affymetrix, High Wy-
combe, UK). The unaffected subjects were all older than
16 years at the time of inclusion. Genotypes were called
by the Genotyping Console (Affymetrix) and uploaded to
the BCSNP data management platform (BC Platforms,
Espoo, Finland) for quality-control filtering (58,958The Americmarkers). Markers with Mendelian errors were detected
with MERLIN19 and removed from the data set. Removal
of monomorphic markers and LD pruning (for which a
sliding window of 50 SNPs and an r2 threshold of 0.5 was
used) was performedwith PLINK20 and resulted in a filtered
data set of 7,199 markers in approximate linkage equilib-
rium with each other. MERLIN was used for the identifica-
tion of unlike genotypes, resulting in the removal of 292
genotypes from the data set. A parametric linkage analysis
assuming autosomal-dominant inheritance with complete
penetrance and a disease gene frequency of 0.0001 was
carried out with MERLIN with allele frequencies from the
Affymetrix 100K frequency files (CEU population) and
genetic distances from the Affymetrix 100K Marshfield
cMmap. Two possible linked loci were identified (on chro-
mosomes 14q31-32 and 6q27-qter), each with a maximum
LOD score of 3.01 (Figure S1 in the Supplemental Data
available online). A follow-up analysis with microsatellite
markers (D14S1037, D14S68, D14S81, D14S65, D6S305,
D6S386, and D6S1590) in these two regions was performed
and included an additional six subjects from the family
(one affected, IV:1; two unaffected, III:10 and III:11; and
three healthy married-in individuals, II:1, II:5, and II:7).
In total, 18 individuals with the microsatellite markers
were genotyped. Primer sequences were retrieved from
the NCBI UniSTS database. The microsatellite analysis
excluded the locus on chromosome 6 and mapped the
disease locus to chromosome 14 (LOD score 3.9)
(Figure 2A).
A haplotype analysis confirmed the presence of the
chromosome 14 disease haplotype in all affected and
none of the unaffected individuals (Figure 1A), suggesting
100% penetrance of the mutation in this family. The peak
on chromosome 14 extended approximately 21 cM,
from rs9323782 (86.6Mb) to rs721403 (95.7Mb) (hg19)
(Table S2), a region that harbors around 70 genes (Figure S2
and Table S3). Because of the pivotal role of calmodulin
in calcium signaling and heart contraction, CALM1
was selected for sequencing. Primers amplifying the
coding regions, adjacent splice sites, and the 50- and
30- untranslated regions of CALM1 were designed with
Primer324 (Table S1). The amplified products were purified
and sequenced on both strands at MWG (Eurofins MWG
Operon, Ebersberg, Germany). Sequencing one affected
family member (the index case) and one unaffected family
member revealed a heterozygous missense mutation
c.161A>T [GenBank NM_006888.4] in exon 3. This muta-
tion results in a change from asparagine (Asn) to isoleucine
(Ile), p.Asn53Ile (UniProtKB P62158, notated without the
initiator methionine residue to reflect the mature pro-
cessed calmodulin) in the index case (Figure 2B). A
genotyping assay for p.Asn53Ile for the LightCycler 480
instrument (Roche, Hvidovre, Denmark) was developed
by TIB MOLBIOL (Berlin, Germany) (Table S1). Genotyp-
ing with LightCycler 480 Genotyping Master Mix (Roche)
confirmed that the p.Asn53Ile substitution was present in
all affected individuals and absent in all of the unaffectedan Journal of Human Genetics 91, 703–712, October 5, 2012 705
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Figure 2. Genome-wide Linkage Analysis and Position of the Calmodulin Mutations
(A) A locus for a severe dominantly inherited form of CPVT-like arrhythmia is shown at position 14q31-32 (LOD score 3.9) and harboring
approximately 70 known genes.
(B) CALM1 structure and position of the c.161A>T and c.293A>G mutations identified in two different individuals with ventricular
tachycardia and the sequencing electropherograms of exon 3 and 5 in the case and a control subject.
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individuals in the pedigree. Genotyping of 1,200 control
individuals (500 Danish medical student volunteers from
Aarhus University and 700 anonymous Danish blood
donors) showed that the mutation was absent among
these 2,400 control chromosomes. This sample size
provided an 80% power to detect a variant with a minor-
allele frequency of 0.001,25 verifying that the mutation is
highly unlikely to be a normal but rare sequence variation.
To systematically screen for other mutations in CALM1,
we developed a mutation-detection assay for each of the
five coding exons on the basis of high-resolution melting
(HRM) of amplified PCR products. All assays were carried
out with 480 High Resolution Melting Master (Roche)
and HPLC purified primers (MWG). Sixty-three individ-
uals, referred for RYR2 mutation analysis at the Statens
Serum Institute in Denmark (where genetic testing failed
to identify any RYR2mutation in 61 of these individuals),
were analyzed in duplicate. All samples with aberrant
melting curves, as well as ten control samples with normal
melting curves, were sequenced (primer sequences are
listed in Table S1). From this screening a second heterozy-
gous CALM1 missense mutation was identified in an indi-
vidual of Iraqi origin. The mutation (c.293A>G) was
located in exon 5 and resulted in an asparagine-to-serine
substitution (p.Asn97Ser) (Figure 2B). DNA sequencing re-
vealed that this mutation was absent in the mother and
the father, neither of whom showed signs of heart arrhyth-
mias, demonstrating the presence of a de novomutation in
this individual. A microsatellite marker analysis confirmed
the paternity relationship. The individual with the de
novo CALM1 mutation was a 23-year-old female who
presented at age 4 with a successfully resuscitated, out-of-
hospital cardiac arrest due to VF while she was running.
She made a full neurological recovery and was stabilized
by treatment with b1-adrenergic-receptor blocker. An
initial ECG and echocardiogram were within normal
limits, and there was no evidence of QT prolongation
(not shown). Evaluation of her immediate family was unre-
markable. An exercise ECG and electrophysiological study
undertaken on full betablockade and right ventricular and
coronary angiography were within normal limits. An
initial diagnosis of idiopathic VF was made at the time.
Follow-up ECGs demonstrated prominent U waves in
the anterior leads but no evidence of the long-QT or
Brugada syndromes (Figure 1C upper panel). When she(C) Alignment of calmodulin amino acid sequences from different s
(red residues). Secondary-structure elements are shown in green and
residues are framed. Dots indicate conserved residues, showing that c
few changes in round worms and plants.
(D) The position of the substituted residues in the three-dimensio
(Schro¨dinger, LLC). Left panel: apo-calmodulin (Protein Data Bank
(pdb ID: 1CLL22), Right panel: Ca2þ bound calmodulin-RYR1 pept
spheres; the RYR1 peptide is in red. The two aromatic hydrophobic
residue Asn53 is positioned on the solvent-exposed side of a-helix
domains. Asn97 is one of the Ca2þ-coordinating residues of Ca2þ-b
and the C domain is at the bottom. The Ca2þ- and RYR1-complexed ca
counterclockwise, respectively, around a vertical axis after structural
The Americwas 12 years old, further investigation including signal-
averaged ECG, echocardiography, cardiac MRI, and cold
pressor and procainamide tests were unremarkable. An
exercise ECG while she was off b1-adrenergic-receptor
blocker demonstrated ventricular ectopy with couplets
and triplets of varying morphology into recovery
(Figure 1C, lower panel). These appeared to be bidirec-
tional at times. On this basis, a diagnosis of CPVT was
made, but genetic testing of RYR2, CASQ2, and KCNJ2
failed to identify any mutations in these genes. In a
follow-up genetic test of other arrhythmia-associated
genes, including KCNQ1 (MIM 607542), KCNH2 (MIM
152427), KCNE1 (MIM 176261), KCNE2 (MIM 603796),
and SCN5A (MIM 600163), no mutations were found.
She fainted twice more in her teens, and at age 15 she
suffered a further cardiac arrest. After recovery, an ICD
was implanted, and she remained well but was diagnosed
with systemic lupus erythematosus (SLE [MIM 152700]).
Her mother, aged 62, was asymptomatic until developing
heart failure secondary to adriamycin-induced cardio-
myopathy from breast cancer treatment. She did not
experience syncope or arrhythmia. An ECG demonstrated
left-bundle-branch block and leftward axis deviation. Her
father, aged 66, had suffered nonexertional syncope in
stressful situations, consistent with vasovagal syncope.
His resting ECG was normal, and exercise testing for atyp-
ical chest pain had induced ischemic changes without
arrhythmia. An angiogram was reported as showing unob-
structed coronaries and vasospasm.
Both CALM1 mutations thus appear to induce an early-
onset and highly penetrant phenotype that belongs to
the severe end of the spectrum of CPVT-like arrhythmias.
In accordance with this, an initial response to therapy
with b1-adrenergic-receptor blocker was observed with
subsequent recurrent symptoms both in the Iraqi case
and in individuals III:4 and III:5 in family 1. The fact
that p.Asn97Ser is a de novo substitution is fits well with
the presentation of the associated disease as a highlymalig-
nant form with very early presentation and is consistent
with the RYR2-associated disease, which is commonly
caused by de novo mutations.26
To assess whether CALM1 missense mutations exist
in the general population, a systematic HRM screen of
all five CALM1 coding exons were performed in 500
Danish control individuals. No missense mutations werepecies; the p.Asn53Ile and p.Asn97Ser substitutions are indicated
orange (a-helix and b strand, respectively), and the Ca2þ-binding
almodulin is 100% conserved in all vertebrates and only displays a
nal structural model of native calmodulin prepared with Pymol
[PDB] ID: 1DMO21), Middle panel: Ca2þ-saturated calmodulin
ide complex (PDB ID: 2BCX23). Calcium ions are shown as gray
binding anchors in RYR1 are shown in stick representation. The
C, not in contact with Ca2þ, peptide ligand, or other calmodulin
inding site III. The calmodulin N domain is positioned on top,
lmodulin structures have been rotated roughly 90 and 180 degrees
alignment of the N domains with the apo-calmodulin structure.
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Figure 3. Calcium Binding
The relative Ca2þ binding of the C domain of calmodulin as a
function of total Ca2þ concentration, determined as the change
in the tyrosine fluorescence intensity. The data presents the
average of three independent experiments (þ/ SD); in most cases
the error bars are smaller than the symbols. In comparison to
native calmodulin, p values are as follows: a, p < 0.05; b, p <
0.01; c, p < 0.001; and d, p < 0.0001 (two-way repeated-measures
ANOVA with the Bonferroni multiple comparisons post-hoc test).identified among these 1,000 control chromosomes. In
contrast, three rare silent polymorphisms were identified
(these were present among five control individuals) (Table
S4), stressing the selection pressure against missense muta-
tions in this gene. A specific Iraqi control population was
not investigated because the mutation was de novo, and
themutation rate is likely to be the same in all populations.
No missense mutations in CALM1 (ENST00000356978)
were found from the 1000 Genomes Project (October
2011 release) interrogated through the Project Browser
#ICHG2011 (Ensembl release 63 representing an inte-
grated set of variant calls and INDELS from low-
coverage and exome sequencing data of 1,092 individuals).
A literature search also failed to present evidence for any
previously identified calmodulin mutations. The lack of
identified missense mutations is not surprising given that
calmodulin is known as one of the most conserved mole-
cules throughout evolution, displays an identifical protein
sequence in all vertebrate species, and has evolved only
slightly since the divergence from plants (Figure 2C). The
presence of three independent genes in the human
genome (CALM1-3 [MIM 114180, 114182 and 114183]),
all encoding ubiquitously expressed identical calmodulin
protein molecules, further underscores the selection pres-
sure against any amino acid changes in this classic
calcium-binding protein.
Calmodulin is a148aminoacida-helical protein contain-
ing four classical Ca2þ-binding EF hands that bind one
calcium ion each. It is shaped as a dumbbell and is capable
of mediating a signal consisting of small intracellular
Ca2þ-concentration changes to a multitude of intracellular
targets via fine-tuned differences in the N- and C-domain
affinity for Ca2þ.27 The N domain contains the lower-708 The American Journal of Human Genetics 91, 703–712, Octoberaffinity Ca2þ-binding sites I and II, and the C domain
contains the high-affinity binding sites III and IV. The two
identified substituted residues are located in opposite
domains; the Asn53 residue is positioned on the solvent-
exposed surface of the first a-helix of Ca2þ-binding site II
in the N domain, and the Asn97 residue is one of the Ca2þ
-binding residues of binding site III, located in the calmod-
ulin C domain (Figure 2D). Calmodulin binds to and regu-
lates the activity of a large number of intracellular proteins,
but in none of the published high-resolution calmodulin
structures available are the two substituted residues indirect
contact with any bound protein or peptide, exemplified by
the calmodulin- RYR1 peptide complex in Figure 2D.
To functionally characterize the substitutions, we used a
nested priming approach to amplify the CALM1 cDNA
(primers are listed in Table S1) from a cDNA preparation
from liver mRNA,28 and we ligated this cDNA into a modi-
fied pMAL vector (New England Biolabs, Ipswich, USA)
containing a Tobacco Etch Virus (TEV) protease cleavage
site. Missense mutations were introduced with Quick-
Change Lightning (QIAGEN) (primer sequences are listed
in Table S1). The calmodulin variants were expressed in
Rosetta B cells (EMD Chemicals). All buffers and reagents
were prepared with purified and deionized (>18.2 U resis-
tance) water and plastic vessels, and all laboratory equip-
ment was washed in 1 M HCl and purified water so that
Ca2þ contamination would be minimized. The total Ca2þ
concentration of the utilized buffers was determined to
be between 1 and 3 mM with the Quin-2 fluorogenic
calcium indicator and Calcium Calibration Buffer Kit #1
(Invitrogen) and an Infinite M1000 fluorescence micro-
plate reader (Tecan, Switzerland). Calmodulin proteins
were purified by affinity chromatography (Amylose Resin
[New England Biolabs]), TEV cleavage, anion-exchange
chromatography (Source 15Q 10/10 [GE Healthcare]),
and size-exclusion chromatography (Superdex 75 16/60
[GE Healthcare]). Protein concentrations were determined
by absorption at 280 nm. The identity and integrity of each
protein preparation was confirmed by MALDI-TOF mass
spectometry (Bruker Reflex III [Bruker-Daltronics]).
First, the Ca2þ-binding property of native and variant
calmodulin was investigated. Because calcium binding
leads to a large conformational change in calmodulin
and the C domain contains two tyrosine (Tyr) residues, it
is possible to monitor Ca2þ binding to the C domain by
measuring the changes in intrinsic Tyr fluorescence inten-
sity.29 Calmodulin variants (15 mM) were titrated with
CaCl2 while the intrinsic Tyr fluorescence intensity at
320 nm (277 nm excitation) was recorded on a FluoroMax
4 spectrofluorometer (HORIBA Jobin Yvon) equipped
with a peltier temperature controller set at 37C. The
fractional C domain Ca2þ binding demonstrated a signifi-
cant reduction in the Ca2þ affinity for the p.Asn97Ser
variant (Figure 3), as evidenced by an apparent half-satura-
tion concentration of ~40 mM (equivalent to 2.7 Ca2þ
ions per calmodulin molecule), compared to ~25 mM total
Ca2þ for native calmodulin (1.7 Ca2þ ions/calmodulin5, 2012
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Figure 4. Interaction with RYR2 Peptide
Calmodulin binding to the RYR2-CBD peptide (Arg3581–Leu3611). The RYR2 Trp3586 fluorescence-emission spectrum, normalized to
the maximal fluorescence intensity of the peptide alone, is shown without added calmodulin (RYR) and with a saturating amount of the
indicated calmodulin variants added at (A) low intracellular (100 nM free Ca2þ), (B) moderate (1 mM free Ca2þ), and (C) saturating
(200 mM Ca2þ) concentrations.molecule). The p.Asn53Ile variant, on the other hand,
demonstrated a small, but significantly increased,
C domain Ca2þ saturation and an earlier half saturation
of ~21 mM (1.4 Ca2þ ions/calmodulin molecule). Because
the p.Asn53Ile substitution is located in the N domain of
calmodulin, we suggest that this ‘‘earlier’’ C domain Ca2þ
saturation reflects a decreased N domain Ca2þ affinity
and leads to increased availability of free Ca2þ for the C
domain to bind at lower total Ca2þ concentration. A less
likely possibility is that it reflects an increased positive
inter-domain cooperativity between the N and C domains.
Hence, we show that both variants lead to altered calcium
binding property of calmodulin and that the substituted
residues impose different effects on the distribution of
bound Ca2þ between the N and C domains of calmodulin.
Next, the interaction between the calmodulin variants
and a peptide from RYR2 encompassing the calmod-
ulin binding domain (CBD), RYR2-CBD (R3581-SKKAVWH
KLLSKQRKRAVVACFRMAPLYN-L3611 [Genscript, USA]),
was investigated. In the high-resolution 3D structure of
calmodulin bound to the equivalent peptide from
RYR1, the Ca2þ-bound C domain of calmodulin fully
encloses the single tryptophan (Trp) residue of the RYR
peptide (RYR1 Trp3620, corresponding to RYR2 Trp3586,
Figure 2D). Calcium binding to calmodulin leads to an
N-terminal shift in its binding site on the RYR2-CBD
peptide. This shift is evidenced by a large increase in fluo-
rescence intensity of the RYR2 Trp3586 residue; calmod-
ulin itself does not contain any Trp residues. The intrinsic
fluorescence emission (290–450 nm, at 280 nm excitation)
of RYR2 Trp3586 was monitored with and without addi-
tion of saturating amounts of calmodulin variants under
four different free-Ca2þ concentrations: no free Ca2þ
([Ca2þ]free < 1 nM, buffer including 5 mM EGTA), resting
cardiomyocyte conditions ([Ca2þ]free ~100 nM), excited
conditions ([Ca2þ]free ~1 mM),
30 and saturating Ca2þ condi-
tions (200 mM total Ca2þ), all in 20 mM HEPES; 100 mMThe AmericKCl (pH 7.2). The free-Ca2þ concentrations for excited
and resting conditions were controlled with an EGTA-
Ca2þ buffer system, as previously described.31 A concentra-
tion of 0.5 mM RYR2 peptide was used with no calmodulin
variant added (RYR2 alone), 3 mM calmodulin variant
added (zero and 100 nM [Ca2þ]free), or 1 mM calmodulin
variant added (1 mM [Ca2þ]free and 200 mM total Ca
2þ).
When saturating amounts of calmodulin were added
at low calcium concentrations (100 nM free Ca2þ),
a remarkable difference in the RYR2-CBD binding
mode was demonstrated for p.Asn97Ser as opposed to
p.Asn53Ile and native calmodulin. The p.Asn97Ser variant
only induced a slight blueshift and no increase in fluo-
rescence intensity (Figure 4A), similar to the effect
seen when calmodulin binds to the skeletal myocyte
ryanodine receptor (RYR1)32 binding-domain peptide in
the absence of Ca2þ. In marked contrast, little or no differ-
ence in the RYR2-CBD binding mode was observed
between p.Asn97Ser, p.Asn53Ile, and native calmodulin
at moderate (1 mM free) or saturating (200 mM total)
calcium concentrations (Figures 4B and 4C). Thus, our
data demonstrate that for the p.Asn97Ser substitution,
the calmodulin-RYR2-CBD interaction is defective at low
intracellular Ca2þ concentrations and is restored at
moderate to high Ca2þ concentrations.
It is well established that calmodulin binds directly to
RYR2, and it has been demonstrated that calmodulin
binding decreases the probability that RYR2 has an
open conformation at free-Ca2þ concentrations down to
100 nM,33 corresponding to a low, diastolic Ca2þ concen-
tration, at which we demonstrated a compromised
calmodulin-RYR2-CBD interaction for the p.Asn97Ser
substitution. Hence, the lack of a calmodulin-RYR2 inter-
action at low Ca2þ concentrations would most likely lead
to an increased probability that RYR2 has an open confor-
mation. On this basis, we suggest that p.Asn97Ser, being
a loss-of-function mutation with regard to the RYR2an Journal of Human Genetics 91, 703–712, October 5, 2012 709
interaction, exerts a dominant-negative effect on the RYR2
channel complex and leads to ‘‘inappropriate RYR2 leaki-
ness’’ similar to what is proposed for RYR2 mutations.
This would also explain how one mutated calmodulin
allele out of six encoding identical proteins is sufficient
to cause a dominantly inherited phenotype.
Interestingly, several animal studies have recently sug-
gested that a disturbed calmodulin RYR2 interaction plays a
key role in arrhythmia and heart failure.33–35 For example,
in a study using knock-in mice harboring the human RYR2
CPVT-type substitution p.Arg2474Ser, previously found to
be a model for CPVT36,37 Xu and co-workers investigated
the RYR2-calmodulin interaction and found a markedly
reduced affinity for calmodulin in response to PKA phos-
phorylation, which led the authors to conclude that
a defective interaction between RYR2 and calmodulin is
part of the pathogenic mechanism for CPVT.35 Our results
are the first human data to strongly support the molecular
disease model in which an aberrant calmodulin-RYR2
interaction is causative of CPVT-like arrhythmias.
The p.Asn53Ile substitution did not demonstrate a signif-
icantly compromised RYR2 interaction in the experi-
mental setup used here. One limitation of our work is
that we studied the calmodulin-RYR2 interaction by using
a small peptide fragment (RYR2-CBD) instead of the large
RYR2 molecular complex. Thus, it is at present unclear
whether the p.Asn53Ile substitution affects the function
of RYR2 in vivo. Intriguingly, the Ca2þ-binding property
of p.Asn53Ile was markedly different from the native and
p.Asn97Ser calmodulin, and it is possible that a different
molecular pathogenic mechanism is in play in family 1.
This could be reminiscent of the mechanism suggested
for ANKB mutations in CPVT given that calmodulin regu-
lates, and AnkB is required for correct assembly of,
a number of ion channels and pumps involved in cardio-
myocyte contraction. For example, such ion channels
and pumps include the L-type calcium channel, Naþ/Kþ
ATPase, Naþ/Ca2þ exchanger, and the InsP(3) receptor.12
In the screened clinical sample, which included 63 indi-
viduals who had unspecified arrhythmias or sudden
cardiac death and had been referred for RYR2 screening,
only two CALM1 mutations were detected (both the
family 1 index case and the Iraqi case were included
in this sample). Thus, the frequency of CALM1 mutations
is seemingly low from this finding. However, because
only two individuals were found to be positive for
RYR2 mutations, the frequencies of CALM1 and RYR2
mutations were identical in this sparsely characterized
and heterogeneous sample collection. More accurately
establishing the frequency and phenotypic variation of
CALM1 mutations in CPVT and related disorders will
require screening of large well-characterized clinical
samples. Before this is done, we cannot exclude that
CALM1 is a rare contributor to CPVT.
In conclusion, we have identified two functionally
distinct CALM1 missense mutations that lead to develop-
ment of early-onset CPVT or CPVT-like arrhythmia. Our710 The American Journal of Human Genetics 91, 703–712, Octoberfinding will directly allow presymptomatic genetic diag-
nosis in families in which members with this severe
disorder harbor CALM1mutations, enabling the initiation
of potentially life-saving treatment for children and young
individuals with disease mutations. As a consequence of
our findings, the three calmodulin genes are candidates
for genetic screening of individuals with CPVT-like
arrhythmia and unexplained sudden cardiac death.Supplemental Data
Supplemental Data include two figures and four tables and can be
found with this article online at http://www.cell.com/AJHG/.Acknowledgments
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